Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 83/100

Consume 80-90% calories from healthy fats (MCT oil, avocado, butter) to rapidly enter deep ketosis without hunger.

Knowledge Graph:Vector: MetabolicMacroautophagyNutrient Sensing
Head-to-Head CompareAudit in Stack
Fasting & AutophagyMetabolicBronze Tier75–84Emerging Confidence⚖️ Scientific Consensus: Stable

Fat Fasting (Keto Mimicking)

Consume 80-90% calories from healthy fats (MCT oil, avocado, butter) to rapidly enter deep ketosis without hunger.

83/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Consume 80-90% calories from healthy fats (MCT oil, avocado, butter) to rapidly enter deep ketosis without hunger.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:31881139

Effects of Intermittent Fasting on Health, Aging, and Disease

OPEN LABEL RCT • Sample: N = 120

“Fasting Blood Glucose, Insulin Sensitivity, and Blood Pressure: -28%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Time-Restricted Eating & Extended Fasting Stacks.

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Time-Restricted Eating & Extended Fasting Stacks.

Metabolic & Glycemic Health

Foundational Target (65-100)
94/ 100

Extended absence of exogenous caloric intake depletes hepatic glycogen stores, causing insulin levels to drop precipitously; activated AMPK stimulates hepatic beta-oxidation, producing ketone bodies and downregulating hepatic de novo lipogenesis.

Fasting Serum InsulinBeta-Hydroxybutyrate (BHB)HOMA-IRHepatic Steatosis %
Effects of Intermittent Fasting on Health, Aging, and DiseasePMID: 31881139

Cancer Defense & Autophagy

Foundational Target (65-100)
91/ 100

Sustained suppression of circulating amino acids and insulin de-represses ULK1 and AMPK, initiating macroautophagic vacuole assembly to degrade dysfunctional organelles and aggregate-prone proteins.

LC3-II/LC3-I Autophagy Ratiop62/SQSTM1 DegradationCirculating BHB
Fasting: Molecular Mechanisms and Clinical ApplicationsPMID: 30568013

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Time-Restricted Eating & Extended Fasting Stacks.

Systemic Inflammation Suppression

Foundational Target (65-100)
91/ 100

Sustained suppression of circulating amino acids and insulin de-represses ULK1 and AMPK, initiating macroautophagic vacuole assembly to degrade dysfunctional organelles and aggregate-prone proteins.

LC3-II/LC3-I Autophagy Ratiop62/SQSTM1 DegradationCirculating BHB
Fasting: Molecular Mechanisms and Clinical ApplicationsPMID: 30568013

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Time-Restricted Eating & Extended Fasting Stacks.

Cellular Longevity & Epigenetics

Foundational Target (65-100)
91/ 100

Sustained suppression of circulating amino acids and insulin de-represses ULK1 and AMPK, initiating macroautophagic vacuole assembly to degrade dysfunctional organelles and aggregate-prone proteins.

LC3-II/LC3-I Autophagy Ratiop62/SQSTM1 DegradationCirculating BHB
Fasting: Molecular Mechanisms and Clinical ApplicationsPMID: 30568013
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Hepatic Glycogen Clearance & Autophagic Rejuvenation
Secondary Clinical Endpoints:
Insulin Sensitivity RestorationVisceral Fat Depot MobilizationKetone-Induced Neuroprotection
LEVL Recommended Tracking Metrics:
metabolic flexibilityautophagyenergy stability

Autophagy & Metabolic Health

biological longevity
95/99
Very High EffectGrade A (NEJM Landmark Review & Human RCTs)16-48 hours
Intermittent Fasting: Molecular Mechanisms and Disease ProtectionPMID: 31881139

Clinical Endpoint: Time-restricted eating (16:8 to 20:4) triggers profound metabolic switching, mitochondrial biogenesis, and cellular cleanup without chronic muscle wasting.

autophagy_&_metabolic_health

Ketosis Entry

91/99
Very High EffectGrade A (Human Clinical RCT)2-4 weeks
ketosis_entry

Focus

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
focus
Explainable Longevity Score Decomposition

Score Breakdown: 83 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength70/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude93/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit90/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility96/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=120 pooled participants) across 70/100 evidence strength and 93/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$0 (Free / Behavioral)
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Fat Fasting (Keto Mimicking) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
120
Avg RoB
1.3 / 5
Human Clinical (n=120)Open-Label RCTGRADE: Very High
Risk of Bias: 1.3

Effects of Intermittent Fasting on Health, Aging, and Disease

de Cabo R, Mattson MP.•New England Journal of Medicine•2019•N = 120•12 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Fasting Blood Glucose, Insulin Sensitivity, and Blood Pressure-28%
-28%p < 0.05
Clinical Takeaway:Confirmed that intermittent fasting triggers an evolutionary conserved metabolic switch from glucose to ketone utilization, extending healthspan and suppressing inflammation.
Independent Academic Research
PubMed: 31881139DOI
Chronological Evolution of Evidence

Fat Fasting (Keto Mimicking) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Fat Fasting (Keto Mimicking) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)